Abstract
As testing for neuronal antibodies become more readily available, the spectrum of conditions potentially associated with these autoantibodies has been widening. Voltage-gated calcium channel antibodies (VGCC-Ab) are no exception to this trend. The significance of an elevated VGCC-Ab titer beyond its original clinicopathological correlate, Lambert–Eaton myasthenic syndrome (LEMS) remains undetermined. We sought to determine the diagnostic significance of an elevated serum VGCC-Ab titer in a large single-center cohort of 100 patients. The majority of patients (58%) with elevated VGCC-Ab levels lacked an inflammatory or autoimmune etiology of their neurologic diagnosis. Only six cases (6%) of LEMS and two cases (2%) of SCLC (without LEMS) were identified. No significant differences in antibody titers were seen between the autoimmune and non-autoimmune groups. These findings support the notions that: (a) elevated VGCC-Ab titers without clinical correlation must be interpreted with caution, and (b) the clinical and electrodiagnostic criteria for LEMS should remain the mainstay in the diagnosis of LEMS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lennon VA, Kryzer TJ, Griesmann GE et al (1995) Calcium-channel antibodies in the Lambert–Eaton syndrome and other paraneoplastic syndromes. NEJM 332:1467–1474. https://doi.org/10.1056/NEJM199506013322203
Motomura M, Lang B, Johnston I et al (1997) Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert–Eaton myasthenic syndrome. J Neurol Sci 147:35–42. https://doi.org/10.1016/S0022-510X(96)05303-8
Vincent A, Lang B, Newsom-Davis J (1989) Autoimmunity to the voltage-gated calcium channel underlies the Lambert–Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci 12:496–502
Titulaer MJ, Lang B, Verschuuren JJ (2011) Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 10:1098–1107
McEvoy KM, Windebank AJ, Daube JR, Low PA (1989) 3,4-Diaminopyridine in the treatment of Lambert–Eaton myasthenic syndrome. N Engl J Med 321:1567–1571. https://doi.org/10.1056/NEJM198912073212303
Oh SJ, Claussen GG, Hatanaka Y, Morgan MB (2009) 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 40:795–800. https://doi.org/10.1002/mus.21422
Sanders DB, Massey JM, Sanders LL, Edwards LJ (2000) A randomized trial of 3,4-diaminopyridine in Lambert–Eaton myasthenic syndrome. Neurology 54:603–607
Wirtz PW, Verschuuren JJ, Van Dijk JG et al (2009) Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert–Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 86:44–48. https://doi.org/10.1038/clpt.2009.35
Oh SJ, Shcherbakova N, Kostera-Pruszczyk A et al (2016) Amifampridine phosphate (Firdapse®) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve 53:717–725. https://doi.org/10.1002/mus.25070
Sanders DB, Juel VC, Harati Y et al (2018) 3,4-Diaminopyridine base effectively treats the weakness of Lambert–Eaton myasthenia. Muscle Nerve 57:561–568. https://doi.org/10.1002/mus.26052
Burns TM, Smith GA, Allen JA et al (2016) Editorial by concerned physicians: unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve 53:165–168
Lang B, Wray D, Newsom-Davis J et al (1981) Autoimmune aetiology for myasthenic (Eaton–Lambert) syndrome. Lancet 318:224–226. https://doi.org/10.1016/S0140-6736(81)90474-8
Motomura M, Johnston I, Lang B et al (1995) An improved diagnostic assay for Lambert–Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 58:85–87
Nakao YK, Motomura M, Fukudome T et al (2002) Seronegative Lambert–Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59:1773–1775
Zalewski NL, Lennon VA, Lachance DH et al (2016) P/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments. Muscle Nerve 54:220–227. https://doi.org/10.1002/mus.25027
Abboud H, Rossman I, Mealy MA et al (2017) Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results. J Neurol 264:2284–2292. https://doi.org/10.1007/s00415-017-8627-4
Albadareen R, Gronseth G, Goeden M et al (2017) Paraneoplastic autoantibody panels: sensitivity and specificity, a retrospective cohort. Int J Neurosci 127:531–538. https://doi.org/10.1080/00207454.2016.1207644
Schoser B, Eymard B, Datt J, Mantegazza R (2017) Lambert–Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol 264:1854–1863
Li Y, Jammoul A, Mente K et al (2015) Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center. Muscle Nerve 52:386–391. https://doi.org/10.1002/mus.24559
Jammoul A, Shayya L, Mente K et al (2016) Clinical utility of seropositive voltage-gated potassium channel-complex antibody. Neurol Clin Pract 6:409–418. https://doi.org/10.1212/CPJ.0000000000000268
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical standard
Ethical standards concerning safeguarging patients’ protected health information, in addition to compliance with the Institutional Review Board were strictly adhered to.
Rights and permissions
About this article
Cite this article
Di Lorenzo, R., Mente, K., Li, J. et al. Low specificity of voltage-gated calcium channel antibodies in Lambert–Eaton myasthenic syndrome: a call for caution. J Neurol 265, 2114–2119 (2018). https://doi.org/10.1007/s00415-018-8959-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-018-8959-8